RT Journal Article
SR Electronic
T1 The Brazilian Rare Genomes Project: validation of whole genome sequencing for rare diseases diagnosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.01.21264436
DO 10.1101/2021.10.01.21264436
A1 Campos Coelho, Antonio Victor
A1 Cordeiro de Azevedo, Bruna Mascaro
A1 Lucon, Danielle Ribeiro
A1 Nóbrega, Maria Soares
A1 de Souza Reis, Rodrigo
A1 de Alexandre, Rodrigo Bertollo
A1 Silva Moura, Livia Maria
A1 de Oliveira, Gustavo Santos
A1 Muniz Guedes, Rafael Lucas
A1 Caraciolo, Marcel Pinheiro
A1 Zurro, Nuria Bengala
A1 Cervato, Murilo Castro
A1 de Oliveira Filho, João Bosco
YR 2021
UL http://medrxiv.org/content/early/2021/10/03/2021.10.01.21264436.abstract
AB Rare diseases affect 3.2 to 13.2 million individuals in Brazil. The Brazilian Rare Genomes Project is envisioned to further the implementation of genomic medicine into the Brazilian public healthcare system. Here we report the results of the validation of a whole genome sequencing (WGS) procedure for implementation in a clinical laboratory. In addition, we report data quality for the first 1,200 real world patients sequenced. For the validation, we sequenced a well characterized group of 76 samples, including seven gold standard genomes, using a PCR-free WGS protocol on Illumina Novaseq 6000 equipment. We compared the observed variant calls with their expected calls, observing good concordance for single nucleotide variants (SNVs; mean F-measure = 99.82%) and indels (mean F-measure = 99.57%). Copy number variants and structural variants events detection performances were as expected (F-measures 96.6% and 90.3%, respectively). Our protocol presented excellent intra- and inter-assay reproducibility, with coefficients of variation ranging between 0.03% and 0.20% and 0.02% and 0.09%, respectively. Limitations of the procedure include the inability to confidently detect variants such as uniparental disomy, balanced translocations, repeat expansion variants and low-level mosaicism. In summary, the observed performance of the test was in accordance with that seen in the best centers worldwide. The Rare Genomes Project is an important initiative to improve Brazil’s general population access to the innovative WGS technology which has the potential to reduce the time until diagnosis of rare diseases, bringing pivotal improvements for the quality of life of the affected individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a PROADI/SUS grant, from the Albert Einstein Hospital and The Brazilian Ministry of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study adheres to the Declaration of Helsinki principles for research in human beings and was approved by the Hospital Israelita Albert Einstein's Research Ethics Committee (Sao Paulo, Brazil. Protocol number: CAAE 29567220.4.1001.0071). All individuals provided written consent for WGS testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.